NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. The company is headquartered in Beltsville, Maryland and currently employs 43 full-time employees. The company went IPO on 2019-05-09. The company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Follow-Up Questions
NextCure Inc의 CEO는 누구입니까?
Mr. Michael Richman은 2015부터 회사에 합류한 NextCure Inc의 President입니다.
NXTC 주식의 가격 성능은 어떻습니까?
NXTC의 현재 가격은 $5.66이며, 전 거래일에 increased 0.45% 하였습니다.
NextCure Inc의 주요 사업 주제나 업종은 무엇입니까?
NextCure Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
NextCure Inc의 시가총액은 얼마입니까?
NextCure Inc의 현재 시가총액은 $15.1M입니다
NextCure Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 4명의 분석가가 NextCure Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 5명의 매수, 2명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
